Pharma News

Haemophilia is a rare condition that affects the blood’s ability to clot.

Tirzepatide (Zepbound; Eli Lilly) is now approved for the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, the Food and Drug Administration announced late la...

In a press release posted on FDA’s website, Endo USA, Inc. announced it was voluntarily recalling all lots of Adrenalin Chloride Solution (EPINEPHrine nasal solution, USP) 30 mg/30 mL (1...

The FDA granted fast track designation (FTD) to a multivalent toxoid vaccine candidate from LimmaTech, LBT-SA7, which is designed to prevent skin and soft tissue infections (SSTIs) cau...

Two clinical trials by Merck and GSK both failed on their key secondary endpoints of overall survival in ovarian cancer. Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all.

Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs)...

Ozempic maker Novo Nordisk A/S took two large steps toward meeting demand for its blockbuster drugs, committing $1.2 billion to build a new factory in Denmark shortly after it got the green light for ...

Sangamo’s STAC-BBB is known for its ability to penetrate the blood-brain barrier and transduce neurons.

BioAge Labs has announced a multi-year research collaboration with Novartis – this partnership aims to identify and validate novel therapeutic drug targets by exploring the biological mechanisms und...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European Commission (EC) gave its approval in early December 2024.

Indian drugmakers Aurobindo, Glenmark and Zydus have issued separate sweeping drug recalls over issues pertaining to impurities and labeling. The product pulls were reported in a recent edition of the...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug.